Exelixis Q2 2026 Results Confirm Steady Cabometyx Execution; Pipeline Milestones Intact

What happened

Exelixis reported second-quarter 2026 financial results in line with management’s previously issued guidance, with Cabometyx net product revenue tracking within the $2.325–2.425 billion range. CEO Michael Morrissey emphasized continued commercial and pipeline execution, signaling no operational or regulatory setbacks. The earnings update reinforces the base-case scenario from the DeepValue report, where Cabometyx maintains ~45% RCC TKI share and NET adoption drives mid-teens growth. Zanzalintinib’s pivotal programs remain on track, with the colorectal cancer NDA filing expected to be discussed, though no material new data emerged. Overall, the quarter reaffirms Exelixis’s near-term financial durability but leaves the longer-term thesis tied to zanzalintinib approval and Cabometyx’s patent cliff timeline.

Implication

For investors, Exelixis remains a show-me story where in-line execution validates the status quo but does not warrant a re-rating. The 2026 guidance, reliant on Cabometyx volume growth and modest price increases, appears achievable given the commercial momentum, yet the stock already prices in much of this success. While zanzalintinib represents upside optionality, its revenue contribution is still at least a year away and subject to binary regulatory risk. The looming patent cliff for cabozantinib beyond 2026 and mounting pricing pressures demand a higher margin of safety than current valuations offer. We would look to accumulate on a pullback toward the high $30s or on clearer evidence of above-guidance Cabometyx trends and clean zanzalintinib regulatory progress.

Thesis delta

The Q2 2026 results do not alter the core investment thesis. Cabometyx continues to deliver within expectations, and zanzalintinib’s development timeline appears unchanged, keeping the risk-reward profile steady. Our WAIT rating remains appropriate until there is a material shift in either commercial execution or pipeline de-risking.